Liothyronine (T3) Dosing in Adults
Starting Dose and Initial Titration
For mild hypothyroidism, start liothyronine at 25 mcg once daily, then increase by up to 25 mcg every 1-2 weeks until the usual maintenance dose of 25-75 mcg daily is reached 1. This represents the FDA-approved dosing regimen for straightforward cases.
For myxedema or severe hypothyroidism, begin with 5 mcg daily and increase by 5-10 mcg every 1-2 weeks; once 25 mcg daily is reached, increase by 5-25 mcg every 1-2 weeks until achieving the usual maintenance dose of 50-100 mcg daily 1. The lower starting dose in severe disease reflects the heightened sensitivity of profoundly hypothyroid patients to thyroid hormone.
For simple (non-toxic) goiter, initiate at 5 mcg daily and increase by 5-10 mcg every 1-2 weeks; when 25 mcg daily is reached, increase every 1-2 weeks by 12.5-25 mcg to the usual maintenance dose of 75 mcg daily 1.
Special Populations Requiring Modified Dosing
In elderly patients or those with cardiovascular disease, start at 5 mcg daily and increase only by 5 mcg increments at the recommended intervals 1. This conservative approach is critical because liothyronine has a rapid onset of action and more pronounced cardiovascular effects compared to levothyroxine 1.
Patients with angina pectoris, occult cardiac disease, or advanced age require particularly cautious dosing with low initial doses (5 mcg daily) due to liothyronine's relatively rapid onset of action 1. Starting dosage should be increased by no more than 5 mcg increments at 2-week intervals in these high-risk patients 1.
For children, the maximum dose is 15-20 mcg/kg/day (not to exceed 1.0 g/day) 2. In congenital hypothyroidism, start at 5 mcg daily with 5 mcg increments every 3-4 days; infants may require only 20 mcg daily for maintenance, while 1-year-olds may need 50 mcg daily, and children above 3 years may require full adult dosing 1.
Combination Therapy with Levothyroxine
When adding liothyronine to levothyroxine for patients symptomatic despite adequate LT4 monotherapy, reduce the LT4 dose by 25 mcg/day and add 2.5-7.5 mcg liothyronine once or twice daily as an appropriate starting point 3. This approach minimizes the risk of overtreatment while providing additional T3.
The recommended LT4/LT3 dose ratio for combination therapy is between 13:1 and 20:1 by weight, with LT4 given once daily and the daily LT3 dose split into two doses 4. Currently available combined preparations with LT4/LT3 ratios less than 13:1 are not recommended 4.
Twice-daily administration of low-dose LT3 (0.07 mcg/kg twice daily) in combination with LT4 can predictably increase serum T3 concentration without significant peaks above the reference range 5. This dosing strategy is based on pharmacokinetic modeling showing liothyronine follows a two-compartment model with a rapid distribution phase (half-life 2.3 hours) and slow elimination phase (half-life 22.9 hours) 5.
Once-daily dosing of liothyronine at 30-45 mcg produces significant excursions in serum T3, with peak concentrations reaching 292.8 ± 152.3 ng/dL approximately 1.8 hours after administration 6. These wide swings in serum T3 levels represent a disadvantage of once-daily dosing and support twice-daily administration or sustained-release preparations 1, 6.
Switching from Levothyroxine to Liothyronine
When switching from levothyroxine, thyroid extract, or thyroglobulin to liothyronine, discontinue the other medication, initiate liothyronine at a low dosage, and increase gradually according to patient response 1. Bear in mind that liothyronine has rapid onset of action and residual effects of the other thyroid preparation may persist for the first several weeks of therapy 1.
Monitoring and Titration Strategy
After initiating therapy, measure TSH and free T4 after 6-8 weeks to assess response 2. This interval allows sufficient time to reach steady state and evaluate the adequacy of dosing.
Careful dose titration is essential to avoid iatrogenic hyperthyroidism 2. The rapid onset and dissipation of liothyronine's action, combined with the possibility of more pronounced cardiovascular side effects, requires vigilant monitoring 1.
Patients with atrial fibrillation, cardiac disease, or other serious medical conditions require more frequent monitoring when initiating or adjusting liothyronine therapy 2. In these high-risk patients, consider monitoring within 2 weeks of dose adjustment rather than waiting the full 6-8 weeks.
Patients with subclinical hyperthyroidism (TSH <0.1 mIU/L) should have their dose reduced to avoid complications including bone loss and increased fracture risk 2. Even TSH suppression to 0.1-0.45 mIU/L warrants dose reduction, particularly in elderly or cardiac patients.
Critical Safety Considerations
Severe and prolonged hypothyroidism can lead to decreased adrenocortical activity; when thyroid-replacement therapy is administered, metabolism increases faster than adrenocortical activity, potentially precipitating adrenocortical insufficiency 1. Therefore, in severe and prolonged hypothyroidism, supplemental adrenocortical steroids may be necessary before initiating liothyronine 1.
Morphologic hypogonadism and nephrosis should be ruled out before administering liothyronine; if hypopituitarism is present, the adrenal deficiency must be corrected prior to starting the drug 1. Myxedematous patients are very sensitive to thyroid hormone, so dosage should start at a very low level and increase gradually 1.
In rare instances, liothyronine administration may precipitate a hyperthyroid state or aggravate existing hyperthyroidism 1. Close monitoring for symptoms of thyrotoxicosis (tachycardia, tremor, heat intolerance, weight loss) is essential throughout treatment.
Special Clinical Scenarios
Liothyronine may be preferred over levothyroxine during radioisotope scanning procedures, since induction of hypothyroidism is more abrupt and can be of shorter duration 1. It may also be preferred when impairment of peripheral conversion of T4 to T3 is suspected 1.
For thyroid suppression testing, administer 75-100 mcg/day for 7 days; radioactive iodine uptake is determined before and after hormone administration, with a 50% or greater suppression indicating a normal thyroid-pituitary axis 1. Liothyronine should be administered cautiously in patients with suspected thyroid gland autonomy, as exogenous hormone effects will be additive to the endogenous source 1.
Although liothyronine's metabolic effects persist for a few days following discontinuance, its rapid cutoff makes it suitable for short-term use in specific clinical situations 1.
Evidence Quality and Patient Selection
Fourteen clinical trials have not shown consistent benefit of LT4/LT3 combination therapy over LT4 monotherapy, yet patients reporting benefit continue to generate interest in this approach 7. Combination therapy should be considered solely as an experimental treatment modality 4.
L-T4 + L-T3 combination therapy might be considered as an experimental approach in compliant LT4-treated hypothyroid patients who have persistent complaints despite serum TSH values within the reference range, provided they have previously received support to deal with the chronic nature of their disease and associated autoimmune diseases have been excluded 4. Treatment should only be instituted by accredited internists/endocrinologists and discontinued if no improvement is experienced after 3 months 4.
Trials following almost 1000 patients for almost 1 year indicate that therapy with LT4+LT3 can restore euthyroidism while maintaining normal serum TSH, similar to LT4 monotherapy 3. An observational study of 400 patients with mean follow-up of approximately 9 years did not indicate increased mortality or morbidity risk due to cardiovascular disease, atrial fibrillation, or fractures after adjusting for age when compared with patients taking only LT4 3.